 Amanda Winters
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 17 | 2024 | 531 | 3.560 |
Why?
| | Azacitidine | 10 | 2024 | 129 | 2.320 |
Why?
| | Neoplasm, Residual | 5 | 2024 | 104 | 2.220 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 12 | 2024 | 171 | 2.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 1358 | 1.670 |
Why?
| | Sulfonamides | 11 | 2024 | 447 | 1.640 |
Why?
| | Myelodysplastic Syndromes | 4 | 2020 | 118 | 1.090 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 269 | 0.880 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 93 | 0.730 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2022 | 520 | 0.720 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 209 | 0.720 |
Why?
| | Neurilemmoma | 1 | 2017 | 19 | 0.590 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2017 | 20 | 0.580 |
Why?
| | Hemangiosarcoma | 1 | 2017 | 19 | 0.580 |
Why?
| | Neurofibromatosis 1 | 1 | 2017 | 36 | 0.570 |
Why?
| | Immunotherapy | 1 | 2019 | 487 | 0.520 |
Why?
| | Mutation | 1 | 2024 | 3374 | 0.450 |
Why?
| | Polymerase Chain Reaction | 2 | 2024 | 1002 | 0.370 |
Why?
| | Neoplastic Stem Cells | 4 | 2023 | 330 | 0.360 |
Why?
| | Estrogen Receptor alpha | 1 | 2010 | 121 | 0.340 |
Why?
| | Prognosis | 3 | 2024 | 3366 | 0.340 |
Why?
| | Glycoproteins | 1 | 2010 | 308 | 0.330 |
Why?
| | Receptors, Estrogen | 1 | 2010 | 374 | 0.310 |
Why?
| | Humans | 29 | 2024 | 116098 | 0.300 |
Why?
| | Carrier Proteins | 1 | 2010 | 707 | 0.280 |
Why?
| | Leukemia | 3 | 2018 | 207 | 0.270 |
Why?
| | Retrospective Studies | 7 | 2024 | 12628 | 0.260 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 640 | 0.250 |
Why?
| | Aged, 80 and over | 5 | 2024 | 6481 | 0.250 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4463 | 0.210 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 16 | 0.210 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 10 | 0.200 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 40 | 0.200 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 158 | 0.200 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 52 | 0.200 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 323 | 0.200 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 125 | 0.190 |
Why?
| | Child | 6 | 2023 | 18496 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2022 | 116 | 0.190 |
Why?
| | Disease-Free Survival | 1 | 2022 | 627 | 0.180 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 179 | 0.180 |
Why?
| | Anemia, Sickle Cell | 1 | 2023 | 221 | 0.170 |
Why?
| | Antibodies, Bispecific | 1 | 2019 | 33 | 0.170 |
Why?
| | Recurrence | 1 | 2022 | 948 | 0.170 |
Why?
| | Antigens, CD19 | 1 | 2019 | 97 | 0.170 |
Why?
| | Remission Induction | 1 | 2019 | 240 | 0.170 |
Why?
| | Female | 9 | 2024 | 60239 | 0.170 |
Why?
| | Aged | 6 | 2024 | 19393 | 0.160 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 282 | 0.160 |
Why?
| | Young Adult | 5 | 2022 | 10485 | 0.160 |
Why?
| | Adult | 5 | 2024 | 30833 | 0.160 |
Why?
| | Salvage Therapy | 1 | 2019 | 129 | 0.160 |
Why?
| | Treatment Outcome | 2 | 2024 | 9160 | 0.160 |
Why?
| | Male | 8 | 2024 | 56283 | 0.150 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 2 | 2009 | 63 | 0.150 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 194 | 0.150 |
Why?
| | Hematopoietic Stem Cells | 2 | 2018 | 356 | 0.140 |
Why?
| | Genetic Testing | 1 | 2019 | 385 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 313 | 0.140 |
Why?
| | Computational Biology | 1 | 2019 | 526 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2022 | 2818 | 0.130 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 528 | 0.130 |
Why?
| | Homeostasis | 1 | 2018 | 580 | 0.120 |
Why?
| | Oxidative Phosphorylation | 3 | 2022 | 155 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1754 | 0.120 |
Why?
| | Middle Aged | 4 | 2024 | 27190 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1014 | 0.120 |
Why?
| | Peptide Fragments | 2 | 2009 | 677 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 864 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2009 | 594 | 0.110 |
Why?
| | Glucose | 1 | 2018 | 907 | 0.110 |
Why?
| | Apoptosis | 3 | 2018 | 2387 | 0.100 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2010 | 9 | 0.090 |
Why?
| | Thyroidectomy | 1 | 2010 | 52 | 0.090 |
Why?
| | Insulin Resistance | 1 | 2018 | 1099 | 0.090 |
Why?
| | Membrane Transport Proteins | 1 | 2010 | 137 | 0.090 |
Why?
| | Signal Transduction | 1 | 2022 | 4549 | 0.080 |
Why?
| | Tumor Cells, Cultured | 3 | 2022 | 856 | 0.080 |
Why?
| | Gene Rearrangement | 1 | 2009 | 137 | 0.080 |
Why?
| | Adolescent | 3 | 2022 | 17885 | 0.080 |
Why?
| | Thyroid Neoplasms | 1 | 2010 | 262 | 0.070 |
Why?
| | Infant | 1 | 2020 | 7996 | 0.070 |
Why?
| | Child, Preschool | 1 | 2020 | 9160 | 0.070 |
Why?
| | Stem Cells | 2 | 2020 | 543 | 0.070 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2007 | 178 | 0.070 |
Why?
| | Antigens, CD34 | 1 | 2023 | 97 | 0.060 |
Why?
| | Gene Fusion | 1 | 2022 | 18 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2009 | 1318 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 57 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2022 | 273 | 0.050 |
Why?
| | Allografts | 1 | 2021 | 127 | 0.050 |
Why?
| | Flow Cytometry | 2 | 2018 | 1057 | 0.050 |
Why?
| | Niacinamide | 1 | 2020 | 65 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 52 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 15 | 0.040 |
Why?
| | Electron Transport Complex II | 1 | 2018 | 23 | 0.040 |
Why?
| | Succinate Dehydrogenase | 1 | 2018 | 41 | 0.040 |
Why?
| | Cell Survival | 1 | 2022 | 1028 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 322 | 0.040 |
Why?
| | Colony-Forming Units Assay | 2 | 2009 | 92 | 0.040 |
Why?
| | Translocation, Genetic | 2 | 2009 | 94 | 0.040 |
Why?
| | Fatty Acids | 1 | 2020 | 392 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2022 | 1649 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 212 | 0.040 |
Why?
| | Necrosis | 2 | 2009 | 214 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 563 | 0.040 |
Why?
| | Amino Acids | 1 | 2020 | 457 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2018 | 244 | 0.040 |
Why?
| | Disease Progression | 1 | 2023 | 2450 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 3920 | 0.030 |
Why?
| | Blotting, Western | 2 | 2009 | 1163 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1665 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1827 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2018 | 715 | 0.030 |
Why?
| | Mice | 2 | 2019 | 15123 | 0.030 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2009 | 32 | 0.020 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2009 | 43 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2009 | 67 | 0.020 |
Why?
| | Cytarabine | 1 | 2009 | 52 | 0.020 |
Why?
| | Transcriptional Elongation Factors | 1 | 2009 | 33 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2090 | 0.020 |
Why?
| | Etoposide | 1 | 2009 | 149 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 82 | 0.020 |
Why?
| | Drug Synergism | 1 | 2009 | 315 | 0.020 |
Why?
| | Comet Assay | 1 | 2007 | 18 | 0.020 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2009 | 96 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2007 | 55 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2009 | 181 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2007 | 119 | 0.020 |
Why?
| | Animals | 2 | 2019 | 32245 | 0.020 |
Why?
| | Cell Cycle | 1 | 2009 | 547 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2007 | 555 | 0.020 |
Why?
| | Cell Membrane | 1 | 2007 | 682 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2210 | 0.010 |
Why?
|
|
Winters's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|